These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
560 related articles for article (PubMed ID: 32234534)
1. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Böhm M; Kario K; Kandzari DE; Mahfoud F; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Konstantinidis D; Choi JW; East C; Lee DP; Ma A; Ewen S; Cohen DL; Wilensky R; Devireddy CM; Lea J; Schmid A; Weil J; Agdirlioglu T; Reedus D; Jefferson BK; Reyes D; D'Souza R; Sharp ASP; Sharif F; Fahy M; DeBruin V; Cohen SA; Brar S; Townsend RR; Lancet; 2020 May; 395(10234):1444-1451. PubMed ID: 32234534 [TBL] [Abstract][Full Text] [Related]
2. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Townsend RR; Mahfoud F; Kandzari DE; Kario K; Pocock S; Weber MA; Ewen S; Tsioufis K; Tousoulis D; Sharp ASP; Watkinson AF; Schmieder RE; Schmid A; Choi JW; East C; Walton A; Hopper I; Cohen DL; Wilensky R; Lee DP; Ma A; Devireddy CM; Lea JP; Lurz PC; Fengler K; Davies J; Chapman N; Cohen SA; DeBruin V; Fahy M; Jones DE; Rothman M; Böhm M; Lancet; 2017 Nov; 390(10108):2160-2170. PubMed ID: 28859944 [TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Mahfoud F; Kandzari DE; Kario K; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Dimitriadis K; Choi JW; East C; D'Souza R; Sharp ASP; Ewen S; Walton A; Hopper I; Brar S; McKenna P; Fahy M; Böhm M Lancet; 2022 Apr; 399(10333):1401-1410. PubMed ID: 35390320 [TBL] [Abstract][Full Text] [Related]
4. Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. Böhm M; Townsend RR; Kario K; Kandzari D; Mahfoud F; Weber MA; Schmieder RE; Tsioufis K; Hickey GL; Fahy M; DeBruin V; Brar S; Pocock S Clin Res Cardiol; 2020 Mar; 109(3):289-302. PubMed ID: 32034481 [TBL] [Abstract][Full Text] [Related]
5. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Kandzari DE; Böhm M; Mahfoud F; Townsend RR; Weber MA; Pocock S; Tsioufis K; Tousoulis D; Choi JW; East C; Brar S; Cohen SA; Fahy M; Pilcher G; Kario K; Lancet; 2018 Jun; 391(10137):2346-2355. PubMed ID: 29803589 [TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL; Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612 [TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. Kandzari DE; Townsend RR; Kario K; Mahfoud F; Weber MA; Schmieder RE; Pocock S; Tsioufis K; Konstantinidis D; Choi J; East C; Lauder L; Cohen DL; Kobayashi T; Schmid A; Lee DP; Ma A; Weil J; Agdirlioglu T; Schlaich MP; Shetty S; Devireddy CM; Lea J; Aoki J; Sharp ASP; Anderson R; Fahy M; DeBruin V; Brar S; Böhm M; J Am Coll Cardiol; 2023 Nov; 82(19):1809-1823. PubMed ID: 37914510 [TBL] [Abstract][Full Text] [Related]
8. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Azizi M; Schmieder RE; Mahfoud F; Weber MA; Daemen J; Davies J; Basile J; Kirtane AJ; Wang Y; Lobo MD; Saxena M; Feyz L; Rader F; Lurz P; Sayer J; Sapoval M; Levy T; Sanghvi K; Abraham J; Sharp ASP; Fisher NDL; Bloch MJ; Reeve-Stoffer H; Coleman L; Mullin C; Mauri L; Lancet; 2018 Jun; 391(10137):2335-2345. PubMed ID: 29803590 [TBL] [Abstract][Full Text] [Related]
9. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Kandzari DE; Kario K; Mahfoud F; Cohen SA; Pilcher G; Pocock S; Townsend R; Weber MA; Böhm M Am Heart J; 2016 Jan; 171(1):82-91. PubMed ID: 26699604 [TBL] [Abstract][Full Text] [Related]
10. Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. Böhm M; Tsioufis K; Kandzari DE; Kario K; Weber MA; Schmieder RE; Townsend RR; Kulenthiran S; Ukena C; Pocock S; Ewen S; Weil J; Fahy M; Mahfoud F J Am Coll Cardiol; 2021 Sep; 78(10):1028-1038. PubMed ID: 34474735 [TBL] [Abstract][Full Text] [Related]
11. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. ; Esler MD; Krum H; Sobotka PA; Schlaich MP; Schmieder RE; Böhm M Lancet; 2010 Dec; 376(9756):1903-9. PubMed ID: 21093036 [TBL] [Abstract][Full Text] [Related]
12. Impact of Antihypertensive Medication Changes After Renal Denervation Among Different Patient Groups: SPYRAL HTN-ON MED. Townsend RR; Ferdinand KC; Kandzari DE; Kario K; Mahfoud F; Weber MA; Schmieder RE; Pocock S; Tsioufis K; David S; Steigerwalt S; Walton A; Hopper I; Bertolet B; Sharif F; Fengler K; Fahy M; Hettrick DA; Brar S; Böhm M Hypertension; 2024 May; 81(5):1095-1105. PubMed ID: 38314554 [TBL] [Abstract][Full Text] [Related]